Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 7/20 | 0.71 |
| ▸ | REN | P00797 | 4/20 | 0.71 |
| ▸ | DPP4 | P27487 | 4/20 | 0.66 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.66 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.66 |
| ▸ | FAP | Q12884 | 1/20 | 0.66 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | F2 | P00734 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | LTA4H | P09960 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | PEPD | P12955 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.52 |
| ▸ | HRH1 | P35367 | 1/20 | 0.52 |
| ▸ | THPO | P40225 | 1/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10779361 | 1.00 | ACE (0.71) | ACERENDPP4DPP8DPP9 | |
| SCHEMBL28827157 | 1.00 | ACE (0.71) | ACERENDPP4DPP8DPP9 | |
| SCHEMBL10779357 | 1.00 | ACE (0.71) | ACERENDPP4DPP8DPP9 | |
| SCHEMBL13246639 | 0.94 | ACE (0.64) | ACERENDPP4DPP8DPP9 | |
| SCHEMBL7271773 | 0.94 | ACE (0.64) | ACERENDPP4DPP8DPP9 | |
| SCHEMBL5970696 | 0.90 | ACE (0.57) | ACERENDPP4DPP8DPP9 | |
| SCHEMBL5970700 | 0.90 | ACE (0.57) | ACERENDPP4DPP8DPP9 | |
| SCHEMBL17695412 | 0.88 | DPP4 (0.63) | ACERENDPP4DPP8DPP9 | |
| SCHEMBL31268657 | 0.88 | ACE (0.56) | ACERENDPP4DPP8DPP9 | |
| SCHEMBL31268669 | 0.88 | ACE (0.56) | ACERENDPP4DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | ACE 1190/4885REN 2773/4885DPP4 43/4885 |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | VIP, DNPEP, PEPD | ACE 486/4885REN 3056/4885DPP4 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.